The Medical Letter on Drugs and Therapeutics
Addendum: Relyvrio Withdrawn
Download PDF:   US English
Med Lett Drugs Ther. 2024 Jun 10;66(1704):96   doi:10.58347/tml.2024.1704e
 Select a term to see related articles  Albrioza   amyotrophic lateral sclerosis   Relyvrio   sodium phenylbutyrate   taurursodiol 

Relyvrio, the fixed-dose combination of sodium phenyl-butyrate and taurursodiol that received accelerated approval for treatment of amyotrophic lateral sclerosis (ALS) in 2022 based on a phase 2 trial showing that it slowed functional decline,1 has voluntarily been withdrawn from the market. According to the manufacturer (Amylyx), the decision to withdraw Relyvrio was based on the results of a phase 3, 48-week trial (PHOENIX). The change from baseline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, which measures fine motor, gross motor, bulbar, and respiratory functioning, was not statistically significantly greater with Relyvrio than with placebo.2 Patients who are already taking the combination will be able to receive the drug from the manufacturer free of charge.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article